keyboard_arrow_up

Research 2014:Breast Cancer Therapeutics In Asia-Pacific Markets To 2020

Breast Cancer Therapeutics In Asia-Pacific Markets To 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options

Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Novel HER-2 Positive Therapies Provide Diversified Treatment Options’, which provides in-depth analysis of breast cancer market within the Asia-Pacific (APAC) covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The breast cancer therapeutics market in the four Asia-Pacific (APAC) countries of India, Australia, China and Japan was worth $1.5 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% to $2.5 billion by 2020. Japan had the largest market in 2013 with a value of $872m, or a share of 58%, followed by China with $320m or 21%, and Australia with $234m or 16%. India had the lowest market share and value at 5% and $81m, but is expected to witness the fastest growth over the forecast period with a CAGR of 13.8%, compared to Australia at 7.8% and China and Japan both at 7.7%.

Browse Full Report with TOChttp://www.marketresearchreports.biz/analysis/196711

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer therapeutics in the four APAC markets of Australia, China, India and Japan.

The report includes:

Disease overview, as well as treatment algorithms and treatment usage patterns

Market size and forecast for the APAC breast cancer market from 2013 to 2020

Major marketed products in the APAC region along with a heat map of product performance

In-depth pipeline analysis for global pipeline in breast cancer drugs along with clinical trial failure rate analysis

Key drivers and restraints that have had and are expected to have a significant impact upon the market

Key licensing and co-development agreements that could have impact on growth trends

To Download Full Report with TOC:  http://www.marketresearchreports.biz/sample/sample/196711

Reasons to Buy

The report will enhance your decision-making capability by allowing you to:

Align your product portfolio to the markets with high growth potential

Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth

Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer drugs market

Develop key strategic initiatives based upon an understanding of key focus areas and leading companies

Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

To Read Complete Report with TOC: http://www.marketresearchreports.biz/analysis-details/breast-cancer-therapeutics-in-asia-pacific-markets-to-2020-novel-her-2-positive-therapies-provide-diversified-treatment-options

Table of Contents

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 8

2 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 -Introduction 9

2.1 Breast Cancer 9

2.2 Symptoms 9

2.3 Epidemiology 10

2.4 Pathophysiology 11

2.5 Diagnosis 11

2.6 Prognosis and Disease Staging 12

2.6.1 Classification 13

2.7 Treatment Options 14

2.7.1 Surgery and Radiation Therapy 14

2.7.2 Chemotherapy 14

2.7.3 Hormonal Therapies 15

2.7.4 Targeted Therapies 15

2.7.5 Resistance to Pharmacological Therapies 16

2.7.6 Treatment Guidelines 16

2.7.7 Measuring the Effectiveness of Treatment 18

3 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Marketed Products 20

3.1 Key Marketed Products 20

3.1.1 Herceptin 20

3.1.2 Halaven 22

3.1.3 Avastin 22

3.1.4 Gemzar 23

3.1.5 Taxotere 24

3.1.6 Tykerb 25

3.1.7 Femara 26

3.1.8 Aromasin 26

3.1.9 Zoladex 26

3.1.10 Arimidex 27

3.2 Heat Map for Marketed Products 27

Contact US:

Office: United States

State Tower
90 State Street, Suite 700
Albany, NY 12207
United States


Toll Free: 866-997-4948
Tel: +1-518-618-1030
E-mailsales@marketresearchreports.biz